All In Biotech

Drug Trial Radar · NCT01239797

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma (MM)

Last checked: Nov 20, 2026Latest source record: Jun 1, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 646 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

646

Actual

Start

Jun 20, 2011

Primary completion

Sep 2, 2014

Study completion Apr 21, 2021

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
Collaborators
AbbVie
First posted
Nov 11, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to determine whether the addition of Elotuzumab to Lenalidomide/low-dose Dexamethasone will increase the progression free survival (PFS).

Conditions

  • Lymphoma
  • Multiple Myeloma

Interventions

  • LenalidomideDrug

    Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug

  • DexamethasoneDrug

    Tablets, Oral, 40 mg, weekly, on Days 1, 8, 15, 22, Repeat every 28 days until subject meets criteria for discontinuation of study drug

  • Dexamethasone (Oral)Drug

    On weeks without Elotuzumab dosing: Tablets, Oral, 40mg, Repeat every 28 days until subject meets criteria for discontinuation of study drug. On weeks with Elotuzumab dosing: Tablets, Oral, 28 mg, Repeat every 28 days until subject meets criteria for discontinuation of study drug

  • Dexamethasone (IV)Drug

    On weeks without Elotuzumab dosing: Not Applicable (N/A) On weeks with Elotuzumab dosing: Solution, Intravenous (IV), 8 mg, weekly, Repeat every 28 days until subject meets criteria for discontinuation of study drug

  • Elotuzumab (BMS-901608; HuLuc63)Biological

    Solution, IV, 10 mg/kg, weekly, on Days 1, 8, 15, 22 (cycles 1\&2); Days 1 and 15 (cycles 3 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Median Progression Free Survival (PFS)Time frame: From randomization up to 326 events (up to approximately 38 months)
  2. Objective Response Rate (ORR)Time frame: From randomization up to approximately 38 months

Locations

216 sites in 23 countries. Site status is shown where the registry gives one.

  • Northwest Alabama Cancer Center, Pc

    Muscle Shoals, Alabama

  • Acrc/Arizona Clinical Research Center, Inc.

    Tucson, Arizona

  • Local Institution

    Berkeley, California

  • Local Institution

    Burbank, California

  • Compassionate Cancer Res Grp

    Corona, California

  • Local Institution

    Corona, California

  • San Diego Pacific Oncology& Hematology Associates, Inc

    Encinitas, California

  • Local Institution

    Greenbrae, California

  • Ucla-Division Of Hematology/Oncology

    Los Angeles, California

  • Medical Oncology Care Associates

    Orange, California

  • Sharp Clinical Oncology Research

    San Diego, California

  • Local Institution

    Vallejo, California

  • Local Institution

    Boca Raton, Florida

  • Cancer Care Centers Of Florida

    Brooksville, Florida

  • Mount Sinai Comprehensive Cancer Center

    Miami Beach, Florida

  • Local Institution

    New Port Richey, Florida

  • Cancer Institute Of Florida

    Orlando, Florida

  • Local Institution

    Titusville, Florida

  • Florida Cancer Specialists

    West Palm Beach, Florida

  • Winship Cancer Institute.

    Atlanta, Georgia

  • Georgia Health Science University

    Augusta, Georgia

  • Orchard Healthcare Research Inc.

    Skokie, Illinois

  • Local Institution

    Indianapolis, Indiana

  • Local Institution

    Mishawaka, Indiana

  • Local Institution

    Iowa City, Iowa

  • Local Institution

    Lexington, Kentucky

  • Local Institution

    Louisville, Kentucky

  • Pikeville Medical Center

    Pikeville, Kentucky

  • Cancer Center Of Acadiana At Lafayette General

    Lafayette, Louisiana

  • Local Institution

    Shreveport, Louisiana

  • Local Institution

    Shreveport, Louisiana

  • Willis Knighton Cancer Center

    Shreveport, Louisiana

  • Dana Farber Cancer Inst

    Boston, Massachusetts

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • Henry Ford Health System

    Detroit, Michigan

  • Capitol Comprehensive Cancer Care Center

    Jefferson City, Missouri

  • Local Institution

    Springfield, Missouri

  • Washington University School Of Medicine

    St Louis, Missouri

  • Local Institution

    Las Vegas, Nevada

  • NYU Clinical Cancer Center

    New York, New York

Showing 40 of 216 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.